Antibody-conjugated nanoparticles for therapeutic applications

Current Medicinal Chemistry

Volumn 19, Issue 19, 2012, Pages 3103-3127

  Cardoso, M M ^a   Peca I N ^a   Roque, A C A ^a  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Active targeting; Antibody conjugated nanoparticles; Infectious diseases therapy; Inflammatory diseases therapy; Surface modification; Targeted drug delivery; Tumour therapy

Indexed keywords

ANTIBODY CONJUGATED NANOPARTICLE; AVIDIN; B LYMPHOCYTE RECEPTOR; BEVACIZUMAB; CANCER ANTIBODY; CD19 ANTIGEN; CETUXIMAB; CHIMERIC ANTIBODY; COPOLYMER; DOXORUBICIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; HLA DR ANTIGEN; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; LIPOSOME; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; NANOCARRIER; NANOPARTICLE; PACLITAXEL; PADGEM PROTEIN; RITUXIMAB; SP1049C; STREPTAVIDIN; TRANSFERRIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CONJUGATION; CONTROLLED DRUG RELEASE; DRUG APPROVAL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG TARGETING; ERYTHROCYTE; EXTRACELLULAR MATRIX; HALF LIFE TIME; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; INFLAMMATION; LEUKEMIA; LEWIS CARCINOMA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOID CELL; MALARIA; MELANOMA; MICELLE; MOLECULAR SIZE; MOLECULARLY TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; NANOENCAPSULATION; NEOPLASM; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PHYSICAL CHEMISTRY; PROSTATE CANCER; PROTEIN EXPRESSION; RAJI CELL; REVIEW; SKIN INFLAMMATION; STOMACH CANCER; THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; NANOPARTICLES;

EID: 84863641507     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712800784667     Document Type: Review

References (314)

1. Kreuter, J. In: Nanoparticles; Marcel Dekker: New York, 1994.
2. Gu, F.; Karnik, R.; Wang, A.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.; Farokhzad, O. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2(3), 14-21.
3. Merisko-Liversidge, E.; Liversidge, G.G.; Cooper, E.R. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci., 2003, 18(2), 113-120.
4. Nijhara, R.; Balakrishnan, K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine, 2006, 2(2), 127-136.
5. Cho, K.J.; Wang, X.; Nie, S.M.; Chen, Z.; Shin, D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res., 2008, 14(5), 1310-1316.
6. Wang, X.; Yang, L.L.; Chen, Z.; Shin, D.M. Application of nanotechnology in cancer therapy and imaging. CA Cancer J. Clin., 2008, 58(2), 97-110.
7. Zhang, L.; Gu, F.X.; Chan, J.M.; Wang, A.Z.; Langer, R.S.; Farokhzad, O.C. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther., 2008, 83(5), 761-769.
8. Singh, R.; Lillard, J.W. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86(3), 215-223.
9. Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev., 2001, 53(2), 283-318.
10. Gupta, P.K. Drug targeting in cancer-chemotherapy-a clinical perspective. J. Pharm. Sci., 1990, 79(11), 949-962.
11. Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2(10), 750-763.
12. Langer, R. Drug delivery and targeting. Nature, 1998, 392(6679), 5-10.
13. Kumar, M. Nano and microparticles as controlled drug delivery devices. J. Pharm. Pharm. Sci., 2000, 3(2), 234-258.
14. Lawrence, M. J.; Rees, G. D. Microemulsion-based media as novel drug delivery systems. Adv. Drug Deliv. Rev., 2000, 45(1), 89-121.
15. Lambert, G.; Fattal, E.; Couvreur, P. Nanoparticulate systems for the delivery of antisense oligonucleotides. Adv. Drug Deliv. Rev., 2001, 47(1), 99-112.
16. Brannonpeppas, L. Recent advances on the use of biodegradable microparticles and nanoparticles in controlled drug-delivery. Int. J. Pharm., 1995, 116(1), 1-9.
17. Soppimath, K.S.; Aminabhavi, T.M.; Kulkarni, A.R.; Rudzinski, W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release, 2001, 70(1-2), 1-20.
18. Brigger, I.; Dubernet, C.; Couvreur, P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev., 2002, 54(5), 631-651.
19. Feng, S.S.; Chien, S. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem. Eng. Sci., 2003, 58(18), 4087-4114.
20. Sanz, L.; Blanco, B.; Alvarez-Vallina, L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol., 2004, 25(2), 85-91.
21. van Dijk, M.A.; van de Winkel, J.G.J. Human antibodies as next generation therapeutics. Curr. Opin. Chem. Biol., 2001, 5(4), 368-374.
22. Kohler, G.; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256(5517), 495-497.
23. Roque, A.C.A.; Lowe, C.R.; Taipa, M.A. Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog., 2004, 20(3), 639-654.
24. Sa'adu, A.; Zumla, A. Human monoclonal antibodies: production, use, problems. Postgraduate Medical Science; Monoclonal antibodies: Production, engineering and clinical application, 1995, 85-120.
25. Francisco, J.; Campbell, R.; Iverson, B.; Georgiou, G. Production and fluorescence-activated cell sorting of escherichia-coli expressing a funtional antibody fragment on the external surface. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90(22), 10444-10448.
26. Schaffitzel, C.; Hanes, J.; Jermutus, L.; Pluckthun, A. Ribosome display: an in vitro method for selection and evolution of antibodies from libraries. J. Immunol. Methods, 1999, 231(1-2), 119-135.
27. Winter, G.; Milstein, C., Man-Made antibodies. Nature, 1991, 349(6307), 293-299.
28. Rees, A.; Staunton, D.; Webster, D.; Searle, S.; Henry, A.; Pedersen, J. Antibody designe-beyond the natural limits. Trends Biotechnol., 1994, 12(5), 199-206.
29. Arruebo, M.; Valladares, M.; Gonzalez-Fernandez, A. Antibody-conjugated nanoparticles for biomedical applications. J. Nanomater., 2009, 439389, 24 pp.
30. Jain, R.K. Transport od molecules across tumor vasculature. Cancer Metastasis Rev., 1987, 6(4), 559-593.
31. Weiner, L. Monoclonal antibody therapy of cancer. Semin. Oncol., 1999, 26(5), 43-51.
32. Adams, G.; Schier, R. Generating improved single-chain Fv molecules for tumor targeting. J. Immunol. Methods, 1999, 231(1-2), 249-260.
33. Hudson, P.; Kortt, A. High avidity scFv multimers; diabodies and triabodies. J. Immunol. Methods, 1999, 231(1-2), 177-189.
34. Arndt, K.; Muller, K.; Pluckthun, A. Factors influencing the dimer to monomer transition of an antibody single-chain Fv fragment. Biochemistry, 1998, 37(37), 12918-12926.
35. Holliger, P.; Winter, G. Diabodies: small bispecific antibody fragments. Cancer Immunol. Immunother., 1997, 45(3-4), 128-130.
36. Kortt, A.; Dolezal, O.; Power, B.; Hudson, P. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng., 2001, 18(3), 95-108.
37. Hu, S.; Shivery, L.; Raubitschek, A.; Sherman, M.; Williams, L.; Wong, J.; Shively, J.; Wu, A. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-C(H)3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 1996, 56(13), 3055-3061.
38. Martin, F.; Toniatti, C.; Salvati, A.; Venturini, S.; Ciliberto, G.; Cortese, R.; Sollazzo, M. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. Embo Journal, 1994, 13(22), 5303-5309.
39. Dimasi, N.; Martin, F.; Volpari, C.; Brunetti, M.; Biasiol, G.; Altamura, S.; Cortese, R.; DeFrancesco, R.; Steinkuhler, C.; Sollazzo, M. Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires. J. Virol., 1997, 71(10), 7461-7469.
40. Martin, F.; Steinkuhler, C.; Brunetti, M.; Pessi, A.; Cortese, R.; De Francesco, R.; Sollazzo, M. A loop-mimetic inhibitor of the HCV-NS3 protease derived from a minibody. Protein Eng., 1999, 12(11), 1005-1011.
41. Schmidt, A.; Muller, D.; Mersmann, M.; Wuest, T.; Gerlach, E.; Garin-Chesa, P.; Rettig, W.J.; Pfizenmaier, K.; Moosmayer, D. Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection. Eur. J. Biochem., 2001, 268(6), 1730-1738.
42. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer, 2001, 1(2), 118-129.
43. Von Mehren, M.; Adams, G.P.; Weiner, L.M. Monoclonal antibody therapy for cancer. Annual Review of Medicine-Selected Topics in the Clinical Sciences, 2003, 54, 343-369.
44. Weiner, L.M.; Adams, G.P. New approaches to antibody therapy. Oncogene, 2000, 19(53), 6144-6151.
45. Nobs, L.; Buchegger, F.; Gurny, R.; Allemann, E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug. Chem., 2006, 17(1), 139-145.
46. Nobs, L.; Buchegger, F.; Gurny, R.; Allemann, E. Poly(lactic acid) nanoparticles labeled with biologically active neutravidin (TM) for active targeting. Eur. J. Pharm. Biopharma., 2004, 58(3), 483-490.
47. Beduneau, A.; Saulnier, P.; Benoit, J.P. Active targeting of brain tumors using nanocarriers. Biomaterials, 2007, 28(33), 4947-4967.
48. Sutton, D.; Nasongkla, N.; Blanco, E.; Gao, J. Functionalized micellar systems for cancer targeted drug delivery. Pharm. Res., 2007, 24(6), 1029-1046.
49. Juliano, R.L.; Stamp, D. Pharmacokinetics of liposome-encapsulated anti-tumor drugs-studies with vinblastine, actinomycin-D, Cytosine-arabinoside, and dounomycin. Biochem. Pharmacol., 1978, 27(1), 21-27.
50. Rahman, A.; Husain, S.R.; Siddiqui, J.; Verma, M.; Agresti, M.; Center, M.; Safa, A.R.; Glazer, R.I. Liposome-mediated modulation os multidrug resistance in humam HL-60 leukaemia-cells. J. Natl. Cancer Inst., 1992, 84(24), 1909-1915.
51. Northfelt, D.W.; Martin, F.J.; Working, P.; Volberding, P.A.; Russell, J.; Newman, M.; Aantea, M.A.; Kaplan, L.D. Doxorubicin encapsulated in liposomes containing surface-found polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol., 1996, 36(1), 55-63.
52. Muggia, F.; Hamilton, A. Phase III data on Caelyx (R) in ovarian cancer. Eur. J. Cancer, 2001, 37(9), S15-S18.
53. Farokhzad, O.C.; Langer, R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev., 2006, 58(14), 1456-1459.
54. Arifin, D.Y.; Lee, L.Y.; Wang, C.H. Mathematical modeling and simulation of drug release from microspheres: implications to drug delivery systems. Adv. Drug Deliv. Rev., 2006, 58(12-13), 1274-1325.
55. Gu, F.X.; Karnik, R.; Wang, A.Z.; Alexis, F.; Levy-Nissenbaum, E.; Hong, S.; Langer, R.S.; Farokhzad, O.C. Targeted nanoparticles for cancer therapy. Nano Today, 2007, 2(3), 14-21.
56. Yeo, Y.; Park, K.N. Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch. Pharm. Res., 2004, 27(1), 1-12.
57. Bodmeier, R.; McGinity, J.W. The preparation and evaluation of drug-containing poly(DL-lactide) microspheres formed by the solvent evaporation method. Pharm. Res., 1987, 4(6), 465-471.
58. Pekarek, K. J.; Jacob, J. S.; Mathiowitz, E. Double-walled polymer microspheres for controlled drug-releae. Nature, 1994, 367(6460), 258-260.
59. Food and Drug Administration. http://www.fda.gov/default.htm (accessed July 15, 2011)
60. Avgoustakis, K. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery. Curr. Drug Deliv., 2004, 1(4), 321-333.
61. Anderson, J.M.; Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev., 1997, 28(1), 5-24.
62. Astete, C.E.; Sabliov, C.M. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed., 2006, 17(3), 247-289.
63. Bawa, P.; Pillay, V.; Choonara, Y.E.; du Toit, L.C. Stimuli-responsive polymers and their applications in drug delivery. Biomed. Mater., 2009, 4(2), 15 pp.
64. Lee, E.S.; Oh, K.T.; Kim, D.; Youn, Y.S.; Bae, Y.H. Tumor pH-responsive flower-like micelles of poly(L-lactic acid)-b-poly (ethylene glycol)-b-poly(L-histidine). J. Control. Release, 2007, 123(1), 19-26.
65. Gullotti, E.; Yeo, Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mo. Pharm., 2009, 6(4), 1041-1051.
66. Min, K.H.; Park, K.; Kim, Y.S.; Bae, S.M.; Lee, S.; Jo, H.G.; Park, R.W.; Kim, I.S.; Jeong, S.Y.; Kim, K.; Kwon, I.C. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J. Control. Release, 2008, 127(3), 208-218.
67. Cho, Y.W.; Park, S.A.; Han, T.H.; Son, D.H.; Park, J.S.; Oh, S.J.; Moon, D.H.; Cho, K.J.; Ahn, C.H.; Byun, Y.; Kim, I.S.; Kwon, I.C.; Kim, S.Y. In vivo tumor targeting and radionuclide imaging with self-assembled nanoparticles: mechanisms, key factors, and their implications. Biomaterials, 2007, 28(6), 1236-1247.
68. Stubbs, M.; McSheehy, P.M.J.; Griffiths, J.R.; Bashford, C.L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today, 2000, 6(1), 15-19.
69. Lo, C.L.; Lin, K.M.; Hsiue, G.H. Preparation and characterization of intelligent core-shell nanoparticles based on poly(D, L-lactide)-g-poly(N- isopropyl-acrylamide-co-methacrylic acid). J. Control. Release, 2005, 104(3), 477-488.
70. Han, S.K.; Na, K.; Bae, Y.H. Sulfonamide based pH-sensitive polymeric micelles: physicochemical characteristics and pH-dependent aggregation. Colloids Surfaces A Physicochem. Eng. Aspects, 2003, 214(1-3), 49-59.
71. Hauck, M.L.; Coffin, D.O.; Dodge, R.K.; Dewhirst, M.W.; Mitchell, J.B.; Zalutsky, M.R. A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure. Int. J. Hyperthermia, 1997, 13(3), 307-316.
72. Kong, G.; Braun, R.D.; Dewhirst, M.W. Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size. Cancer Res., 2000, 60(16), 4440-4445.
73. Rapoport, N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog. Polym. Sci., 2007, 32(8-9), 962-990.
74. Galindo-Rodriguez, S.; Allemann, E.; Fessi, H.; Doelker, E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm. Res., 2004, 21(8), 1428-1439.
75. Zambaux, M.F.; Bonneaux, F.; Gref, R.; Maincent, P.; Dellacherie, E.; Alonso, M.J.; Labrude, P.; Vigneron, C. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release, 1998, 50(1-3), 31-40.
76. Feng, S.S.; Huang, G.F. Effects of emulsifiers on the controlled release of paclitaxel (Taxol (R)) from nanospheres of biodegradable polymers. J. Control. Release, 2001, 71(1), 53-69.
77. Mu, L.; Feng, S.S. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol (R)). J. Control. Release, 2002, 80(1-3), 129-144.
78. Niwa, T.; Takeuchi, H.; Hino, T.; Kunou, N.; Kawashima, Y. Preparations of biodegradable nanopheres of water-soluble and insoluble drugs with D, L-lactide glycolide copolymer by a novel spontaneous emulsification solvent diffusion method, and the drug release behavior. J. Control. Release, 1993, 25(1-2), 89-98.
79. Allemann, E.; Leroux, J.C.; Gurny, R.; Doelker, E. In-vitro extended-release properties of drug-loaded poly(DL-lactic acid) nanoparticles produced by a salting-out procedure. Pharm. Res., 1993, 10(12), 1732-1737.
80. Tom, J.W.; Debenedetti, P.G. Particle formation with supercritical fluids-a review. J. Aerosol Sci., 1991, 22(5), 555-584.
81. Randolph, T.W.; Randolph, A.D.; Mebes, M.; Yeung, S. Sub-micrometer-sized biodegradable particles of poly(l-lactic acid) via the gas antisolvent spray precipitation process. Biotechnol. Prog., 1993, 9(4), 429-435
82. Tan, H.S.; Borsadia, S. Particle formation using supercritical fluids: pharmaceutical applications. Expert Opin. Ther. Pat., 2001, 11(5), 861-872.
83. Costa, M.S.; Duarte, A.R.C.; Cardoso, M.M.; Duarte, C.M.M. Supercritical antisolvent precipitation of PHBV microparticles. Int. J. Pharm., 2007, 328(1), 72-77.
84. Mohanraj, V.J.; Chen, Y. Nanoparticles-a review. Trop. J. Pharm. Res., 2006, 5(1), 561-573.
85. Seymour, L.W.; Duncan, R.; Strohalm, J.; Kopecek, J. Effect of molecular-weight (mbarw) of n-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal, and intravenous administration to rats. J. Biomed. Mater. Res., 1987, 21(11), 1341-1358.
86. Moghimi, S.M.; Porter, C.J.H.; Muir, I.S.; Illum, L.; Davis, S.S. non-phagocytic uptake of intravenously injected microspheres in rat spleen-influence of particle-size and hydrophilic coating. Biochem. Biophys. Res. Commun., 1991, 177(2), 861-866.
87. Muller, R.H.; Souto, E.B.; Goppert, T.; Gohla, S. In: Biological and Pharmaceutical Nanomaterials; C. Kumar, Ed.; Wiley VCH: New York, 2006; pp. 287-303.
88. Moghimi, S.M.; Patel, H.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-the concept of tissue specificity. Adv. Drug Deliv. Rev., 1998, 32(1-2), 45-60.
89. Senior, J.; Gregoriadis, G. Is half-life of curculating liposomes determined by changes in their permeability. FEBS Lett., 1982, 145(1), 109-114.
90. Senior, J.; Crawley, J.C.W.; Gregoriadis, G. Tissue distribution of liposmies exhibiting long kalf-lives in the circulation after intravenous-injection. Biochim. Biophys. Acta, 1985, 839(1), 1-8.
91. Storm, G.; Belliot, S.O.; Daemen, T.; Lasic, D.D. surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv. Drug Deliv. Rev., 1995, 17(1), 31-48.
92. Gref, R.; Minamitake, Y.; Peracchia, M.T.; Trubetskoy, V.; Torchilin, V.; Langer, R. Biodegradable long-circulating polymeric nanospheres. Science, 1994, 263(5153), 1600-1603.
93. Maitra, A. In: Handbook of Surface and Colloid; Birdi, K.S., Ed.; CRC Press: Denmark, 1997; pp. 603-611.
94. Allen, T.M. Long-circulating (sterically stabilized) liposomes for targeted drug-delivery. Trends Pharmacol. Sci., 1994, 15(7), 215-220.
95. Va n Vlerken, L.E.; Vyas, T.K.; Amiji, M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res., 2007, 24(8), 1405-1414.
96. Shenoy, D.B.; Amiji, M.A. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm., 2005, 293(1-2), 261-270.
97. Tada, H.; Higuchi, H.; Wanatabe, T.M.; Ohuchi, N. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res., 2007, 67(3), 1138-1144.
98. Park, J.W.; Hong, K.L.; Kirpotin, D.B.; Colbern, G.; Shalaby, R.; Baselga, J.; Shao, Y.; Nielsen, U.B.; Marks, J.D.; Moore, D.; Papahadjopoulos, D.; Benz, C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res., 2002, 8(4), 1172-1181.
99. Sapra, P.; Allen, T.M. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res., 2002, 62(24), 7190-7194.
100. Bennis, S.; Chapey, C.; Couvreur, P.; Robert, J. Enhanced cytotoxicity of doxorubicin encapsulated in polyisohexylcyanoacrylate nanospheres against multidrug-resistant tumor-cells in culture. Eur. J. Cancer, 1994, 30A(1), 89-93.
101. Larsen, A.K.; Escargueil, A.E.; Skladanowski, A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol. Ther., 2000, 85(3), 217-229.
102. Peer, D.; Karp, J.M.; Hong, S.; FaroKhzad, O.C.; Margalit, R.; Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol., 2007, 2(12), 751-760.
103. Pastan, I.; Hassan, R.; FitzGerald, D.J.; Kreitman, R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer, 2006, 6(7), 559-565.
104. de Menezes, D.E.L; Pilarski, L.M.; Allen, T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res., 1998, 58(15), 3320-3330.
105. Chapman, A.P. PEGylated antibodies and antibody fragments for improved therapy: a review. Adv. Drug Deliv. Rev., 2002, 54(4), 531-545.
106. Cooper, M.A. Optical biosensors in drug discovery. Nat. Rev. Drug Discov., 2002, 1(7), 515-528.
107. Pietronave, S.; Iafisco, M.; Locarno, D.; Rimondini, L.; Prat, M. Functionalized nanomaterials for diagnosis and therapy of cancer. J. Appl. Biomater. Biomech., 2009, 7(2), 77-89.
108. Melton, R.G. Preparation and purification of antibody-enzyme conjugates for therapeutic applications. Adv. Drug Deliv. Rev., 1996, 22(3), 289-301.
109. Green, N.M. Avidin and streptavidin. Methods Enzymol., 1990, 184, 51-67.
110. Pardridge, W.M. Vector-mediated peptide drug-delivery to the brain. Adv. Drug Deliv. Rev., 1995, 15(1-3), 109-146.
111. Phillips, N.C.; Gagne, L.; Tsoukas, C.; Dahman, J. Immunoliposome targeting to murine cd4(+) leukocytes is dependent on immune status. J. Immunol., 1994, 152(6), 3168-3174.
112. Wartlick, H.; Michaelis, K.; Balthasar, S.; Strebhardt, K.; Kreuter, J.; Langer, K. Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells. J. Drug Target., 2004, 12(7), 461-471.
113. Dinauer, N.; Balthasar, S.; Weber, C.; Kreuter, J.; Langer, K.; Von Briesen, H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials, 2005, 26(29), 5898-5906.
114. Klibanov, A.L.; Maruyama, K.; Beckerleg, A.M.; Torchilin, V.P.; Huang, L. Activity of amphipathic poly(ethylene glycol)-5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim. Biophys. Acta, 1991, 1062(2), 142-148.
115. Torchilin, V.P. Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. Immunomethods, 1994, 4(3), 244-58.
116. Allen, T.M.; Brandeis, E.; Hansen, C.B.; Kao, G.Y.; Zalipsky, S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta, 1995, 1237(2), 99-108.
117. Hansen, C.B.; Kao, G.Y.; Moase, E.H.; Zalipsky, S.; Allen, T.M. Attachment of antibodies to sterically stabilized liposomes-evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta, 1995, 1239(2), 133-144.
118. Shahinian, S.; Silvius, J.R. A novel strategy affords high-yield coupling of antibody fab' fragments to liposomes. Biochim. Biophys. Acta, 1995, 1239(2), 157-167.
119. Maruyama, K.; Takizawa, T.; Yuda, T.; Kennel, S.J.; Huang, L.; Iwatsuru, M. Targetability of novel immunoliposomes modified with amphipathic poly(ethylene glycol)s conjugated at their distal terminals to monoclonal-antibodies. Biochim. Biophys. Acta, 1995, 1234(1), 74-80.
120. Huwyler, J.; Wu, D.F.; Pardridge, W.M. Brain drug delivery of small molecules using immunoliposomes. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93(24), 14164-14169.
121. Nie, S.M.; Xing, Y.; Kim, G.J.; Simons, J.W. Nanotechnology applications in cancer. Annu. Rev. Biomed. Eng., 2007, 9, 257-288.
122. Hatakeyama, H.; Akita, H.; Ishida, E.; Hashimoto, K.; Kobayashi, H.; Aoki, T.; Yasuda, J.; Obata, K.; Kikuchi, H.; Ishida, T.; Kiwada, H.; Harashima, H. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int. J. Pharm., 2007, 342(1-2), 194-200.
123. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.L.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66(13), 6732-6740.
124. Sugano, M.; Egilmez, N.K.; Yokota, S.J.; Chen, F.A.; Harding, J.; Huang, S.K.; Bankert, R.B. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res., 2000, 60(24), 6942-6949.
125. ElBayoumi, T.A.; Torchilin, V.P. Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol. Pharm., 2009, 6(1), 246-254.
126. El Bayoumil, T.; Torchilin, V.P. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin. Cancer Res., 2009, 15(6), 1973-1980.
127. Pirollo, K.F.; Rait, A.; Zhou, Q.; Hwang, S.H.; Dagata, J.A.; Zon, G.; Hogrefe, R.I.; Palchik, G.; Chang, E.H. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res., 2007, 67(7), 2938-2943.
128. Sapra, P.; Moase, E.H.; Ma, J.; Allen, T.M., Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments. Clin. Cancer Res., 2004, 10(3), 1100-1111.
129. Allen, T.M.; Mumbengegwi, D.R.; Charrois, G.J.R. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin. Cancer Res., 2005, 11(9), 3567-3573.
130. Sapra, P.; Allen, T.M. Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res., 2004, 10(14), 4893-4893.
131. Cheng, W.W.K.; Allen, T.M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J. Control. Release, 2008, 126(1), 50-58.
132. Tuscano, J.M.; Martin, S.M.; Ma, Y.P.; Zamboni, W.; O'Donnell, R.T. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-hodgkin's lymphoma xenograft mouse model. Clin. Cancer Res., 2010, 16(10), 2760-2768.
133. Matsumura, Y.; Gotoh, M.; Muro, K.; Yamada, Y.; Shirao, K.; Shimada, Y.; Okuwa, M.; Matsumoto, S.; Miyata, Y.; Ohkura, H.; Chin, K.; Baba, S.; Yama, T.; Kannami, A.; Takamatsu, Y.; Ito, K.; Takahashi, K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Annals Oncol., 2004, 15(3), 517-525.
134. Hosokawa, S.; Tagawa, T.; Niki, H.; Hirakawa, Y.; Nohga, K.; Nagaike, K. Efficacy of immunoliposomes on cancer models in a cell-surface-antigen-density- dependent manner. British J. Cancer, 2003, 89(8), 1545-1551.
135. Raffaghello, L.; Pagnan, G.; Pastorino, F.; Cosimo, E.; Brignole, C.; Marimpietri, D.; Bogenmann, E.; Ponzoni, M.; Montaldo, P.G. Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma. Cancer Lett., 2003, 197(1-2), 151-155.
136. Pastorino, F.; Brignole, C.; Marimpietri, D.; Sapra, P.; Moase, E.H.; Allen, T.M.; Ponzoni, M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res., 2003, 63(1), 86-92.
137. Gupta, B.; Torchilin, V.P. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother., 2007, 56(8), 1215-1223.
138. Schnyder, A.; Krahenbuhl, S.; Drewe, J.; Huwyler, J. Targeting of daunomycin using biotinylated immunoliposomes: Pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Target., 2005, 13(5), 325-335.
139. Pan, X.G.; Wu, G.; Yang, W.L.; Barth, R.F.; Tjarks, W.; Lee, R.J. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug. Chem., 2007, 18(1), 101-108.
140. Feng, B.; Tomizawa, K.; Michiue, H.; Miyatake, S.; Han, X.J.; Fujimura, A.; Seno, M.; Kirihata, M.; Matsui, H. Delivery of sodium borocaptate to glioma cells using immunoliposome conjugated with anti-EGFR antibodies by ZZ-His. Biomaterials, 2009, 30(9), 1746-1755.
141. Everts, M.; Koning, G.A.; Kok, R.J.; Asgeirsdottir, S.A.; Vestweber, D.; Meijer, D.K.F.; Storm, G.; Molema, G. In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharm. Res., 2003, 20(1), 64-72.
142. Van der Veen, B.S.; Asgeirsdottir, S.A.; Zwiers, P.J.; Molema, G.; Heeringa, P. Induction of CXCR2 expression and its ligands in experimental anti-MPO IgG induced glomerulonephritis. Clin. Exp. Rheumatol., 2007, 25(1), S91-S91.
143. Gagne, J.F.; Desormeaux, A.; Perron, S.; Tremblay, M.J.; Bergeron, M.G. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta, 2002, 1558(2), 198-210.
144. Bestman-Smith, J.; Gourde, P.; Desormeaux, A.; Tremblay, M.J.; Bergeron, M.G. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim. Biophys. Acta, 2000, 1468(1-2), 161-174.
145. Owais, M.; Varshney, G.; Choudhury, A.; Chandra, S.; Gupta, C. Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant plasmodium-berghei infections in mice. Antimicrob. Agents Chemother., 1995, 39(1), 180-184.
146. Agrawal, A.; Singhal, A.; Gupta, C. Functional-drug targeting to erythrocytes invivo using antibody bearing liposomes as drug vehicles. Biochem. Biophys. Res. Commun., 1987, 148(1), 357-361.
147. Chandra, S.; Agrawal, A.; Gupta, C. Chloroquine delivery to erythrocytes in plasmodium berghei-infected mice using antibody-bearing liposomes as drug vehicles. J. Biosci., 1991, 16(3), 137-144.
148. Chen, H.; Gao, J.; Lu, Y.; Kou, G.; Zhang, H.; Fan, L.; Sun, Z.; Guo, Y.; Zhong, Y. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control. Release, 2008, 128(3), 209-216.
149. Muro, S.; Dziubla, T.; Qiu, W.N.; Leferovich, J.; Cui, X.; Berk, E.; Muzykantov, V.R. Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1. J. Pharmacol. Exp. Ther., 2006, 317(3), 1161-1169.
150. Liu, P.; Li, Z.; Zhu, M.; Sun, Y.; Li, Y.; Wang, H.; Duan, Y. Preparation of EGFR monoclonal antibody conjugated nanoparticles and targeting to hepatocellular carcinoma. J. Mater. Sci. Mater. Med., 2010, 21(2), 551-556.
151. Debotton, N.; Parnes, M.; Kadouche, J.; Benita, S. Overcoming the formulation obstacles towards targeted chemotherapy: in vitro and in vivo evaluation of cytotoxic drug loaded immunonanoparticles. J. Control. Release, 2008, 127(3), 219-230.
152. Li, L.Y.; Wartchow, C.A.; Danthi, S.N.; Shen, Z.M.; Dechene, N.; Pease, J.; Choi, H.S.; Doede, T.; Chu, P.; Ning, S.C.; Lee, D.Y.; Bednarski, M.D.; Knox, S.J. A novel antiangiogenesis therapy using an integrin antagonist or anti-FLK-1 antibody coated Y-90-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys., 2004, 58(4), 1215-1227.
153. Aktas, Y.; Yemisci, M.; Andrieux, K.; Gursoy, R.N.; Alonso, M.J.; Fernandez-Megia, E.; Novoa-Carballal, R.; Quinoa, E.; Riguera, R.; Sargon, M.F.; Celik, H.H.; Demir, A.S.; Hincal, A.A.; Dalkara, T.; Capan, Y.; Couvreur, P. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem., 2005, 16(6), 1503-1511.
154. Sakhalkar, H.S.; Dalal, M.K.; Salem, A.K.; Ansari, R.; Fu, A.; Kiani, M.F.; Kurjiaka, D.T.; Hanes, J.; Shakesheff, K.M.; Goetz, D.J. Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100(26), 15895-15900.
155. Jin, C.; Qian, N.S.; Zhao, W.; Yang, W.Q.; Bai, L.; Wu, H.; Wang, M.C.; Song, W.J.; Dou, K.F. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. Biomacromolecules, 2010, 1 (9), 2422-2431.
156. World Health Organization. http://www.who.int (accessed August 4 2011)
157. Ruoslahti, E.; Bhatia, S.N.; Sailor, M.J. Targeting of drugs and nanoparticles to tumors. J. Cell Biol., 2010, 188(6), 759-768.
158. Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2004, 56(11), 1649-1659.
159. Abou-Jawde, R.; Choueiri, T.; Alemany, C.; Mekhail, T. An overview of targeted treatments in cancer. Clin. Ther., 2003, 25(8), 2121-2137.
160. Kim, C.K.; Lim, S.J. Recent progress in drug delivery systems for anticancer agents. Arch. Pharm. Res., 2002, 25(3), 229-239.
161. Liu, Y.Y.; Miyoshi, H.; Nakamura, M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int. J. Cancer, 2007, 120(12), 2527-2537.
162. Byrne, J.D.; Betancourt, T.; Brannon-Peppas, L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev., 2008, 60(15), 1615-1626.
163. Park, K.; Lee, S.; Kang, E.; Kim, K.; Choi, K.; Kwon, I.C. New generation of multifunctional nanoparticles for Cancer Imaging and Therapy. Adv. Funct. Mater., 2009, 19(10), 1553-1566.
164. Jain, K.K. Advances in the field of nanooncology. BMC Med., 2010, 8, 83.
165. Arias, J.L. Drug targeting strategies in cancer treatment: an overview. Mini Rev. Med. Chem., 2011, 11(1), 1-17.
166. Arias, J.L. Drug delivery strategies in targeting cancer: current concepts and future developments. Curr. Drug Targets, 2011, 12(8), 1094-1095.
167. Kateb, B.; Chiu, K.; Black, K.L.; Yamamoto, V.; Khalsa, B.; Ljubimova, J.Y.; Ding, H.; Patil, R.; Portilla-Arias, J.A.; Modo, M.; Moore, D.F.; Farahani, K.; Okun, M.S.; Prakash, N.; Neman, J.; Ahdoot, D.; Grundfest, W.; Nikzad, S.; Heiss, J.D. Nanoplatforms for constructing new approaches to cancer treatment, imaging, and drug delivery: what should be the policy? Neuroimage, 2011, 54(1), S106-S124.
168. Mishra, B.; Patel, B.B.; Tiwari, S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine, 2010, 6(1), 9-24.
169. Fay, F.; Scott, C.J. Antibody-targeted nanoparticles for cancer therapy. Immunotherapy, 2011, 3(3), 381-394.
170. Grossfeld, G.D.; Carroll, P.R.; Lindeman, N.; Meng, M.W.; Groshen, S.; Feng, A.C.; Hawes, D.; Cote, R.J. Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression. Urology, 2002, 59(1), 97-102.
171. Jones, A.; Harris, A.L. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy. Cancer J. Sci. Am., 1998, 4(4), 209-217.
172. Teicher, B.A. Molecular targets and cancer therapeutics: discovery, development and clinical validation. Drug Resist. Updat., 2000, 3(2), 67-73.
173. Maitra, A. In: Handbook of Surface and Colloid; Birdi, K.S., Ed.; CRC Press: Boca Raton, 1997; pp. 603-611.
174. Hobbs, S.K.; Monsky, W.L.; Yuan, F.; Roberts, W.G.; Griffith, L.; Torchilin, V.P.; Jain, R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95(8), 4607-4612.
175. Maeda, H.; Matsumura, Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 1989, 6(3), 193-210.
176. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer-chemotherapy-mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986, 46(12), 6387-6392.
177. Dienst, A.; Grunow, A.; Unruh, M.; Rabausch, B.; Nor, J.E.; Fries, J.W.U.; Gottstein, C. Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins. J. Natl. Cancer Inst., 2005, 97(10), 733-747.
178. Ferrara, N.; Hillan, K.J.; Novotny, W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun., 2005, 333(2), 328-335.
179. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res., 2000, 60(2), 203-212.
180. Fiedler, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D.K. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukaemia. Blood, 1997, 89(6), 1870-1875.
181. Liu, B.; Earl, H.M.; Baban, D.; Shoaibi, M.; Fabra, A.; Kerr, D.J.; Seymour, L.W. Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF. Biochem. Biophys. Res. Commun., 1995, 217(3), 721-727.
182. Chen, J.; Wu, H.; Han, D.Y.; Xie, C.S. Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer. Cancer Lett., 2006, 231(2), 169-175.
183. Huang, K.H.; Liu, J.H.; Wang, L.Y.; Zhu, Z.H.; Chen, Q.K.; Min, J.; Chen, R.F. Study of the anti-tumor effect of anti-vascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles. Zhonghua Wei Chang Wai Ke Za Zhi, 2007, 10(5), 482-485.
184. Mousa, S.A. Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications. Curr. Opin. Chem. Biol., 2002, 6(4), 534-541.
185. Nisato, R.E.; Tille, J.-C.; Jonczyk, A.; Goodman, S.L.; Pepper, M.S. Alphavbeta3 and alphavbeta5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis, 2003, 6(2), 105-119.
186. Brooks, P.C.; Stromblad, S.; Klemke, R.; Visscher, D.; Sarkar, F.H.; Cheresh, D.A. Antiintegrin alpha-v-beta-3 blocks human breast-cancer growth and angiogenesis in human skin. J. Clin. Invest., 1995, 96(4), 1815-1822.
187. Feldinghabermann, B.; Mueller, B.M.; Romerdahl, C.A.; Cheresh, D.A. Involvement of integrin alpha-v gene-expression in human-melanoma tumorigenicity. J. Clin. Invest., 1992, 89(6), 2018-2022.
188. Brooks, P.C.; Montgomery, A.M.P.; Rosenfeld, M.; Reisfeld, R.A.; Hu, T.H.; Klier, G.; Cheresh, D.A. Integrin alpha(v)beta(3) antagonists promote tumor-regression by inducing apoptosis of angiogenic blood-vessels. Cell, 1994, 79(7), 1157-1164.
189. Wagner, S.; Rothweiler, F.; Anhorn, M.G.; Sauer, D.; Riemann, I.; Weiss, E.C.; Katsen-Globa, A.; Michaelis, M.; Cinatl, J.; Schwartz, D.; Kreuter, J.; von Briesen, H.; Langer, K. Enhanced drug targeting by attachment of an anti alpha v integrin antibody to doxorubicin loaded human serum albumin nanoparticles. Biomaterials, 2010, 31(8), 2388-2398.
190. Osborn, L.; Hession, C.; Tizard, R.; Vassallo, C.; Luhowskyj, S.; Chirosso, G.; Lobb, R. Direct expression cloning of vascular cell-adhesion molecule-1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell, 1989, 59(6), 1203-1211.
191. Tsourkas, A.; Shinde-Patil, V.R.; Kelly, K.A.; Patel, P.; Wolley, A.; Allport, J.R.; Weissleder, R. In vivo imaging of activated endothelium using an anti-VCAM-1 magnetooptical probe. Bioconjug. Chem., 2005, 16(3), 576-581.
192. Gosk, S.; Moos, T.; Gottstein, C.; Bendas, G. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim. Biophys. Acta, 2008, 1778(4), 854-863.
193. Genis, L.; Galvez, B.G.; Gonzalo, P.; Arroyo, A.G. MT1-MMP: universal or particular player in angiogenesis? Cancer Metastasis Rev., 2006, 25(1), 77-86.
194. Kondo, M.; Asai, T.; Katanasaka, Y.; Sadzuka, Y.; Tsukada, H.; Ogino, K.; Taki, T.; Baba, K.; Oku, N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer, 2004, 108(2), 301-306.
195. Sato, H.; Takino, T.; Miyamori, H. Roles of membrane-type matrix metalloproteinase-1 in tumor invasion and etastasis. Cancer Sci., 2005, 96(4), 212-217.
196. Yana, I.; Seiki, M. MT-MMPs play pivotal roles in cancer dissemination. Clin. Exp. Metastasis, 2002, 19(3), 209-215.
197. Laskin, J.J.; Sandier, A.B. Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat. Rev., 2004, 30(1), 1-17.
198. Harries, M.; Smith, I. The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer, 2002, 9(2), 75-85.
199. Sun, B.; Feng, S.S. Trastuzumab-functionalized nanoparticles of biodegradable copolymers for targeted delivery of docetaxel. Nanomedicine, 2009, 4(4), 431-445.
200. Anhorn, M.G.; Wagner, S.; Kreuter, J.; Langer, K.; Von Briesen, H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug. Chem., 2008, 19(12), 2321-2331.
201. Cirstoiu-Hapca, A.; Bossy-Nobs, L.; Buchegger, F.; Gurny, R.; Delie, F. Differential tumor cell targeting of anti-HER2 (Herceptin (R)) and anti-CD20 (Mabthera (R)) coupled nanoparticles. Int. J. Pharm., 2007, 331(2), 190-196.
202. Kocbek, P.; Obermajer, N.; Cegnar, M.; Kos, J.; Kristl, J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J. Control. Release, 2007, 120(1-2), 18-26.
203. Chen, H.W.; Gao, J.; Lu, Y.; Kou, G.; Zhang, H.; Fan, L.; Sun, Z.G.; Guo, Y.J.; Zhong, Y.Q. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J. Control. Release, 2008, 128(3), 209-216.
204. Sun, B.; Ranganathan, B.; Feng, S.S. Multifunctional poly(D, L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer. Biomaterials, 2008, 29(4), 475-486.
205. Liu, Y.T.; Li, K.; Liu, B.; Feng, S.S. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials, 2010, 31(35), 9145-9155.
206. Singh, M. Transferrin as a targeting ligand for liposomes and anticancer drugs. Curr. Pharm. Des., 1999, 5(6), 443-451.
207. Xu, L.; Huang, C.C.; Huang, W.Q.; Tang, W.H.; Rait, A.; Yin, Y.Z.; Cruz, I.; Xiang, L.M.; Pirollo, K.F.; Chang, E.H. Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther., 2002, 1(5), 337-346.
208. Barth, B.M.; Sharma, R.; Altinoglu, E.I.; Morgan, T.T.; Shanmugavelandy, S.S.; Kaiser, J.M.; McGovern, C.; Matters, G.L.; Smith, J.P.; Kester, M.; Adair, J.H. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano, 2010, 4(3), 1279-87.
209. Siegel, R.; Ward, E.; Brawley, O.; Jemal, A.J. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin., 2011, 61(4), 212-236.
210. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human-breast cancer-correlation of relapse and survival with amplification of the her-2 neu oncogene. Science, 1987, 235(4785), 177-182.
211. World Health Organization. Globocan Programme. http://www.globocan.iarc. fr (accessed August 4, 2011).
212. Azarmi, S.; Roa, W.H.; Loebenberg, R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev., 2008, 60(8), 863-875.
213. Woodward, J.D.; Kennel, S.J.; Mirzadeh, S.; Dai, S.; Wall, J.S.; Richey, T.; Avenell, J.; Rondinone, A.J. In vivo SPECT/CT imaging and biodistribution using radioactive (CdTe)-Te-125m/ZnS nanoparticles. Nanotechnology, 2007, 18(17), 5 pp.
214. Debotton, N.; Zer, H.; Parnes, M.; Harush-Frenkel, O.; Kadouche, J.; Benita, S. A quantitative evaluation of the molecular binding affinity between a monoclonal antibody conjugated to a nanoparticle and an antigen by surface plasmon resonance. Eur. J. Pharm. Biopharm., 2010, 74(2), 148-156.
215. Muro, S.; Muzykantov, V. R. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr. Pharm. Des., 2005, 11(18), 2383-2401.
216. Rossin, R.; Muro, S.; Welch, M.J.; Muzykantov, V.R.; Schuster, D.P. In vivo imaging of Cu-64-labeled polymer nanoparticles targeted to the lung endothelium. J. Nucl. Med., 2008, 49(1), 103-111.
217. Kou, G.; Gao, J.; Wang, H.; Chen, H.W.; Li, B.H.; Zhang, D.P.; Wang, S.H.; Hou, S.; Qian, W.Z.; Dai, J.X.; Zhong, Y.Q.; Guo, Y.J. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J. Biochem. Mol. Biol., 2007, 40(5), 731-739.
218. Sultana, A.; Smith, C.T.; Cunningham, D.; Starling, N.; Tait, D.; Neoptolemos, J.P.; Ghaneh, P. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. B r. J. Cancer, 2007, 96(8), 1183-1190.
219. Yu, X.J.; Zhang, Y.Q.; Chen, C.Y.; Yao, Q.Z.; Li, M. Targeted drug delivery in pancreatic cancer. Biochim. Biophys. Acta, 2010, 1805(1), 97-104.
220. Bruckner, H.W.; Hrehorovich, V.R.; Sawhney, H.S. Bevacizumab as treatment for chemotherapy-resistant pancreatic cancer. Anticancer Res., 2005, 25(5), 3637-3639.
221. Li, M.; Bharadwaj, U.; Zhang, R.X.; Zhang, S.; Mu, H.; Fisher, W.E.; Brunicardi, F.C.; Chen, C.Y.; Yao, Q.Z. Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer. Mol. Cancer Ther., 2008, 7(2), 286-296.
222. Hassan, R.; Bullock, S.; Premkumar, A.; Kreitman, R.J.; Kindler, H.; Willingham, M.C.; Pastan, I. Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin. Cancer Res., 2007, 13(17), 5144-5149.
223. Ona, F.V.; Zamcheck, N.; Dhar, P.; Moore, T.; Kupchik, H.Z. Carcinoembryonic antigen (cea) in diagnosis of pancreatic cancer. Cancer, 1973, 31(2), 324-327.
224. Hu, C.M.J.; Kaushal, S.; Cao, H.S.T.; Aryal, S.; Sartor, M.; Esener, S.; Bouvet, M.; Zhang, L.F. Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells. Mol. Pharm., 2010, 7(3), 914-920.
225. Jelinkova, M.; Strohalm, J.; Etrych, T.; Ulbrich, K.; Rihova, B. Starlike vs. classic macromolecular prodrugs: two different antibody-targeted HPMA copolymers of doxorubicin studied in vitro and in vivo as potential anticancer drugs. Pharm. Res., 2003, 20(10), 1558-1564.
226. Fay, F.; McLaughlin, K.M.; Small, D.M.; Fennell, D.A.; Johnston, P.G.; Longley, D.B.; Scott, C.J. Conatumumab (AMG 655) coated nanoparticles for targeted pro-apoptotic drug delivery. Biomaterials, 2011, 32(33), 8645-53.
227. Gerber, H.P.; Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med. (Berl), 2003, 81(1), 20-31.
228. Griffin, J.D.; Linch, D.; Sabbath, K.; Larcom, P.; Schlossman, S.F. A monoclonal-antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res., 1984, 8(4), 521-534.
229. Bicho, A.; Peca, I.; Roque, A.; Cardoso, M.M. Anti-CD8 conjugated nanoparticles to target mammalian cells expressing CD8. Int. J. Pharm., 2010, 399(1-2), 80-86.
230. Gururangan, S.; Friedman, H.S. Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clin. N. Am., 2002, 12(4), 583-597.
231. Pardridge, W.M. Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem. Res., 1998, 23(5), 635-644.
232. Engelhardt, B.; Sorokin, L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin. Immunopathol., 2009, 31(4), 497-511.
233. Saito, Y.; Wright, E.M. Bicarbonate transport across the frog choroid-plexus and its control by cyclic-nucleotides. J. Physiol., 1983, 336(MAR), 635-648.
234. Pardridge, W.M. Drug delivery to the brain. J. Cereb. Blood Flow Metab., 1997, 17(7), 713-731.
235. Golden, P.L.; Pollack, G.M. Blood-brain barrier efflux transport. J. Pharm. Sci., 2003, 92(9), 1739-1753.
236. Pardridge, W.M. Blood-brain barrier delivery. Drug Discov. Today, 2007, 12(1-2), 54-61.
237. DiMeco, F.; Li, K.W.; Tyler, B.M.; Wolf, A.S.; Brem, H.; Olivi, A. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J. Neurosurg., 2002, 97(5), 1173-1178.
238. Lesniak, M.S.; Upadhyay, U.; Goodwin, R.; Tyler, B.; Brem, H. Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res., 2005, 25(6B), 3825-3831.
239. Westphal, M.; Hilt, D.C.; Bortey, E.; Delavault, P.; Olivares, R.; Warnke, P.C.; Whittle, I.R.; Jaaskelainen, J.; Ram, Z. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol., 2003, 5(2), 79-88.
240. Pardridge, W.M. Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm. Sci. Technolo. Today, 1999, 2(2), 49-59.
241. Sinkula, A.A.; Yalkowsky, S.H. Rationale for design of biologically reversible drug derivatives-prodrugs. J. Pharm. Sci., 1975, 64(2), 181-210.
242. Cosolo, W.C.; Martinello, P.; Louis, W.J.; Christophidis, N. Blood-brain-barrier disruption using mannitol-time course and electron-microscopy studies. Am. J. Physiol., 1989, 256(2), R443-R447.
243. Cloughesy, T.F.; Black, K.L. Pharmacological blood-brain barrier modification for selective drug delivery. J. Neurooncol., 1995, 26(2), 125-132.
244. Agarwal, A.; Lariya, N.; Saraogi, G.; Dubey, N.; Agrawal, H.; Agrawal, G.P. Nanoparticles as novel carrier for brain delivery: a review. Curr. Pharm. Des., 2009, 15(8), 917-925.
245. Alam, M.I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharm. Sci., 2010, 40(5), 385-403.
246. Misra, A.; Ganesh, S.; Shahiwala, A.; Shah, S.P. Drug delivery to the central nervous system: a review. J. Pharm. Pharm. Sci., 2003, 6(2), 252-273.
247. Gao, X.; Chen, J.; Tao, W.; Zhu, J.; Zhang, Q.; Chen, H.; Jiang, X. UEA I-bearing nanoparticles for brain delivery following intranasal administration. Int. J. Pharm., 2007, 340(1-2), 207-215.
248. Kreuter, J.; Ramge, P.; Petrov, V.; Hamm, S.; Gelperina, S.E.; Engelhardt, B.; Alyautdin, R.; Von Briesen, H.; Begley, D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res., 2003, 20(3), 409-416.
249. Steiniger, S.C.J.; Kreuter, J.; Khalansky, A.S.; Skidan, I.N.; Bobruskin, A.I.; Smirnova, Z.S.; Severin, S.E.; Uhl, R.; Kock, M.; Geiger, K.D.; Gelperina, S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer, 2004, 109(5), 759-767.
250. Petri, B.; Bootz, A.; Khalansky, A.; Hekmatara, T.; Mueller, R.; Uhl, R.; Kreuter, J.; Gelperina, S. Chemotherapy of brain turnour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J. Control. Release, 2007, 117, 51-58.
251. Schafer, V.; Vonbriesen, H.; Andreesen, R.; Steffan, A.M.; Royer, C.; Troster, S.; Kreuter, J.; Rubsamenwaigmann, H. Phagocytosis of nanoparticles by human-immunodeficiency-virus (hiv)-infected macrophages-a possibility for antiviral drug targeting. Pharm. Res., 1992, 9(4), 541-546.
252. Kreuter, J. In: Nanoparticles as Drug Carriers; Imperial College Press: London, 2006; pp. 527-547.
253. Allen, D.D.; Geldenhuys, W.J. Molecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous system. Life Sci., 2006, 78(10), 1029-1033.
254. Nagasawa, K.; Ito, S.; Kakuda, T.; Nagai, K.; Tamai, I.; Tsuji, A.; Fujimoto, S. Transport mechanism for aluminum citrate at the blood-brain barrier: kinetic evidence implies involvement of system Xc(-) immortalized rat brain endothelial cells. Toxicol. Lett., 2005, 155(2), 289-296.
255. Bickel, U.; Yoshikawa, T.; Pardridge, W.M. Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 2001, 46(1-3), 247-279.
256. Pardridge, W.M.; Eisenberg, J.; Yang, J. Human blood-brain-barrier insulin-receptor. J. Neurochem., 1985, 44(6), 1771-1778.
257. Pardridge, W.M.; Eisenberg, J.; Jing, Y. Human blood-brain-barrier transferrin receptor. Metabolism, 1987, 36(9), 892-895.
258. Triguero, D.; Buciak, J.B.; Yang, J.; Pardridge, W.M. Blood-brain-barrier transport of cationized immunoglobulin-g-enhanced delivery compared to native protein. Proceedings of the National Academy of Sciences of the United States of America, 1989, 86(12), 4761-4765.
259. Pardridge, W.M.; Triguero, D.; Buciak, J.; Yang, J. Evaluation of cationized rat albumin as a potential blood-brain-barrier drug transport vector. J. Pharmacol. Exp. Ther., 1990, 255(2), 893-899.
260. Jefferies, W.A.; Brandon, M.R.; Hunt, S.V.; Williams, A.F.; Gatter, K.C.; Mason, D.Y. transferrin receptor on endothelium of brain capillaries. Nature, 1984, 312(5990), 162-163.
261. Hall, W.A. Transferrin receptor on glioblastoma-multiforme. J. Neurosurg., 1991, 74(2), 313-314.
262. Zhang, Y.; Lee, H.J.; Boado, R.J.; Pardridge, W.M. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med., 2002, 4(2), 183-194.
263. Podlecki, D.A.; Smith, R.M.; Kao, M.; Tsai, P.; Huecksteadt, T.; Brandenburg, D.; Lasher, R.S.; Jarett, L.; Olefsky, J.M. Nuclear translocation of the insulin-receptor-a possible mediator of insulins long-term effects. J. Biol. Chem., 1987, 262(7), 3362-3368.
264. Pardridge, W.M.; Buciak, J.L.; Friden, P.M. Selective transport of an antitransferrin receptor antibody through the blood-brain-barrier invivo. J. Pharmacol. Exp. Ther., 1991, 259(1), 66-70.
265. Huwyler, J.; Yang, J.; Pardridge, W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther., 1997, 282(3), 1541-1546.
266. Schnyder, A.; Krahenbuhl, S.; Torok, M.; Drewe, J.; Huwyler, J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem. J., 2004, 377(1), 61-67.
267. Sauter, G.; Maeda, T.; Waldman, F.M.; Davis, R.L.; Feuerstein, B.G. Patterns of epidermal growth factor receptor amplification in malignant gliomas. Am. J. Pathol., 1996, 148(4), 1047-1053.
268. Olivier, J.C.; Huertas, R.; Lee, H.J.; Calon, F.; Pardridge, W.M. Synthesis of pegylated immunonanoparticles. Pharm. Res., 2002, 19(8), 1137-1143.
269. Ulbrich, K.; Hekmatara, T.; Herbert, E.; Kreuter, J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm., 2009, 71(2), 251-256.
270. Tsutsui, Y.; Tomizawa, K.; Nagita, M.; Michiue, H.; Nishiki, T.; Ohmori, I.; Seno, M.; Matsui, H. Development of bionanocapsules targeting brain tumors. J. Control. Release, 2007, 122(2), 159-164.
271. Ulbrich, W.; Lamprecht, A. Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases. J. R. Soc. Interface, 2010, 7(1), S55-S66.
272. Turner, N.C.; Wright, N.A. In: Oxford Textbook of Pathology; Oxford University Press Eds.: Oxford, 1992; pp. 351-390.
273. Boerman, O.C.; Oyen, W.J.G.; Storm, G.; Corvo, M.L.; vanBloois, L.; vanderMeer, J.W.M.; Corstens, F.H.M. Technetium-99m labelled liposomes to image experimental arthritis. Ann. Rheum. Dis., 1997, 56(6), 369-373.
274. Boerman, O.C.; Oyen, W.J.G.; vanBloois, L.; Koenders, E.B.; vanderMeer, J.W.M.; Corstens, F.H.M.; Storm, G. Optimization of technetium-99m-labeled PEG liposomes to image focal infection: effects of particle size and circulation time. J. Nucl. Med., 1997, 38(3), 489-493.
275. Dams, E.T.M.; Oyen, W.J.G.; Boerman, O.C.; Storm, G.; Laverman, P.; Koenders, E.B.; van der Meer, J.W.M.; Corstens, F.H.M. Technetium-99m-labeled liposomes to image experimental colitis in rabbits: Comparison with technetium-99m-HMPAO-granulocytes and technetium-99m-HYNIC-IgG. J. Nucl. Med., 1998, 39(12), 2172-2178.
276. Dams, E.T.M.; Becker, M.J.; Oyen, W.J.G.; Boerman, O.C.; Storm, G.; Laverman, P.; de Marie, S.; van der Meer, J.W.M.; Bakker-Woudenberg, I.; Corstens, F.H.M. Scintigraphic imaging of bacterial and fungal infection in granulocytopenic rats. J. Nucl. Med., 1999, 40(12), 2066-2072.
277. Dams, E.T.M.; Oyen, W.J.G.; Boerman, O.C.; Storm, G.; Laverman, P.; Kok, P.J.M.; Buijs, W.; Bakker, H.; van der Meer, J.W.M.; Corstens, F.H.M. Tc-99m-PEG liposomes for the scintigraphic detection of infection and inflammation clinical evaluation. J. Nucl. Med., 2000, 41(4), 622-630.
278. Simone, E.; Ding, B.-S.; Muzykantov, V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res., 2009, 335(1), 283-300.
279. Pober, J.S.; Cotran, R.S.The role of endothelial-cells in inflammation. Transplantation, 1990, 50(4), 537-544.
280. Chellat, F.; Merhi, Y.; Moreau, A.; Yahia, L. Therapeutic potential of nanoparticulate systems for macrophage targeting. Biomaterials, 2005, 26(35), 7260-7275.
281. Misko, T.P.; Trotter, J.L.; Cross, A.H. Mediation of inflammation by encephalitogenic cells-interferon-gamma induction of nitric-oxide synthase and cyclooxygenase-2. J. Neuroimmunol., 1995, 61(2), 195-204.
282. Benveniste, E.N. Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. J. Mol. Med. (Berl), 1997, 75(3), 165-173.
283. Koch, A.E.; Burrows, J.C.; Haines, G.K.; Carlos, T.M.; Harlan, J.M.; Leibovich, S.J. Immunolocalization of endothelial and leukocyte adhesion molecules in human rheumatoid and osteoarthritic synovial tissues. Lab. Invest., 1991, 64(3), 313-320.
284. Jones, S.P.; Trocha, S.D.; Strange, M.B.; Granger, D.N.; Kevil, C.G.; Bullard, D.C.; Lefer, D.J. Leukocyte and endothelial cell adhesion molecules in a chronic murine model of myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2000, 279(5), H2196-H2201.
285. Malizia, G.; Calabrese, A.; Cottone, M.; Raimondo, M.; Treidosiewicz, L.K.; Smart, C.J.; Oliva, L.; Pagliaro, L. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel-disease. Gastroenterology, 1991, 100(1), 150-159.
286. Wegner, C.D.; Gundel, R.H.; Reilly, P.; Haynes, N.; Letts, L.G.; Rothlein, R. Intercellular-adhesion molecule-1 (icam-1) in the pathogenesis of asthma. Science, 1990, 247(4941), 456-459.
287. Forrest, M.J.; Eiermann, G.J.; Meurer, R.; Walakovits, L.A.; Macintyre, D.E. The role of cd18 in il-8 induced dermal and synovial inflammation. Br. J. Pharmacol., 1992, 106(2), 287-294.
288. Gundel, R.H.; Wegner, C.D.; Torcellini, C.A.; Clarke, C.C.; Haynes, N.; Rothlein, R.; Smith, C.W.; Letts, L.G. Endothelial leukocyte adhesion molecule-1 mediates antigen-induced acute airway inflammation and late-phase airway-obstruction in monkeys. J. Clin. Invest., 1991, 88(4), 1407-1411.
289. Gundel, R. H.; Wegner, C.D.; Torcellini, C.A.; Letts, L.G. The role of intercellular-adhesion molecule-1 in chronic airway inflammation. Clin. Exp. Allergy, 1992, 22(5), 569-575.
290. Weg, V.B.; Williams, T.J.; Lobb, R.R.; Nourshargh, S. A monoclonal-antibody recognizing very late activation antigen-4 inhibits eosinophil accumulation invivo. J. Exp. Med., 1993, 177(2), 561-566.
291. Uwatoku, T.; Shimokawa, H.; Abe, K.; Matsumoto, Y.; Hattori, T.; Oi, K.; Matsuda, T.; Kataoka, K.; Takeshita, A. Application of nanoparticle technology for the prevention of restenosis after balloon injury in rats. Circ. Res., 2003, 92(7), E62-E69.
292. Kolodgie, F.D.; John, M.; Khurana, C.; Farb, A.; Wilson, P.S.; Acampado, E.; Desai, N.; Soon-Shiong, P.; Virmani, R. Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel. Circulation, 2002, 106(10), 1195-1198.
293. Richards, P.J.; Williams, B.D.; Williams, A.S. Suppression of chronic streptococcal cell wall-induced arthritis in Lewis rats by liposomal clodronate. Rheumatology, 2001, 40(9), 978-987.
294. Ishihara, T.; Kubota, T.; Choi, T.; Higaki, M. Treatment of experimental arthritis with stealth-type polymeric nanoparticles encapsulating betamethasone phosphate. J. Pharmacol. Exp. Ther., 2009, 329(2), 412-417.
295. Huitinga, I.; Vanrooijen, N.; Degroot, C.J.A.; Uitdehaag, B.M.J.; Dijkstra, C.D. Suppression of experimental allergic encephalomyelitis in lewis rats after elimination of macrophages. J. Exp. Med., 1990, 172(4), 1025-1033.
296. Bauer, J.; Huitinga, I.; Zhao, W.G.; Lassmann, H.; Hickey, W.F.; Dijkstra, C.D. The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia, 1995, 15(4), 437-446.
297. Calvo, P.; Gouritin, B.; Villarroya, H.; Eclancher, F.; Giannavola, C.; Klein, C.; Andreux, J.P.; Couvreur, P. Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the rat. Eur. J. Neurosci., 2002, 15(8), 1317-1326.
298. Cavaletti, G.; Cassetti, A.; Canta, A.; Galbiati, S.; Gilardini, A.; Oggioni, N.; Rodriguez-Menendez, V.; Fasano, A.; Liuzzi, G. M.; Fattler, U.; Ries, S.; Nieland, J.; Riccio, P.; Haas, H. Cationic liposomes target sites of acute neuroinflammation in experimental autoimmune encephalomyelitis. Mol. Pharm., 2009, 6(5), 1363-1370.
299. Linker, R.A.; Weller, C.; Luehder, F.; Mohr, A.; Schmidt, J.; Knauth, M.; Metselaar, J.M.; Gold, R. Liposomal glucocorticosteroids in treatment of chronic autoimmune demyelination: long-term protective effects and enhanced efficacy of methylprednisolone formulations. Exp. Neurol., 2008, 211(2), 397-406.
300. Schmidt, J.; Metselaar, J.M.; Wauben, M.H.M.; Toyka, K.V.; Storm, G.; Gold, R. Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosis. Brain, 2003, 126(8), 1895-1904.
301. Muro, S.; Gajewski, C.; Koval, M.; Muzykantov, V.R. ICAM-1 recycling in endothelial cells: a novel pathway for sustained intracellular delivery and prolonged effects of drugs. Blood, 2005, 105(2), 650-658.
302. Muro, S.; Wiewrodt, R.; Thomas, A.; Koniaris, L.; Albelda, S.M.; Muzykantov, V.R.; Koval, M. A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1. J. Cell Sci., 2003, 116(8), 1599-1609.
303. Asgeirdottir, S.A.; Zwiers, P.J.; Morselt, H.W.; Moorlag, H.E.; Bakker, H.I.; Heeringa, P.; Kok, J.W.; Kallenberg, C.G.M.; Molema, G.; Kamps, J.A.A.M. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasone-loaded Ab(Esel) liposomes. Am. J. Physiol. Renal Physiol., 2008, 294(3), F554-F561.
304. Bender, A.; Schafer, V.; Steffan, A.M.; Royer, C.; Kreuter, J.; Rubsamenwaigmann, H.; Vonbriesen, H. Inhibition of hiv in-vitro by antiviral drug-targeting using nanoparticles. Res. Virol., 1994, 145(3-4), 215-220.
305. Bender, A.R.; vonBriesen, H.; Kreuter, J.; Duncan, I.B.; RubsamenWaigmann, H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother., 1996, 40(6), 1467-1471.
306. Cohen, O.J.; Pantaleo, G.; Lam, G.K.; Fauci, A.S. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin. Immunopathol., 1997, 18(3), 305-322.
307. Arthur, L.O.; Bess, J.W.; Sowder, R.C.; Benveniste, R.E.; Mann, D.L.; Chermann, J.C.; Henderson, L.E. Cellular proteins bound to immunodeficiency viruses-implications for pathogenesis and vaccines. Science, 1992, 258(5090), 1935-1938.
308. Schapira, A.; Beales, P.; Halloran, M. Malaria-living with drug-resistance. Parasitol. Today, 1993, 9(5), 168-174.
309. Santos-Magalhaes, N.S.; Mosqueira, V.C.F. Nanotechnology applied to the treatment of malaria. Adv. Drug Deliv. Rev., 2010, 62(4-5), 560-575.
310. Singhal, A.; Gupta, C. Antibody-mediated targeting of liposomes to red-cells in vivo. FEBS Lett., 1986, 201(2), 321-326.
311. Agrawal, A.; Gupta, C. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliv. Rev., 2000, 41(2), 135-146.
312. Murciano, J.C.; Muro, S.; Koniaris, L.; Christofidou-Solomiclou, M.; Harshaw, D.W.; Albelda, S.M.; Granger, D.N.; Cines, D.B.; Muzykantov, V.R. ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface. Blood, 2003, 101(10), 3977-3984.
313. Wiewrodt, R.; Thomas, A.P.; Cipelletti, L.; Christofidou-Solomidou, M.; Weitz, D.A.; Feinstein, S.I.; Schaffer, D.; Albelda, S.M.; Koval, M.; Muzykantov, V.R. Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells. Blood, 2002, 99(3), 912-922.
314. Yurko, Y.; Maximov, V.; Andreozzi, E.; Thompson, G.L.; Vertegel, A.A. Design of biomedical nanodevices for dissolution of blood clots. Mater. Sci. Eng. C Biomimetic Supramol. Syst., 2009, 29(3), 737-741.